查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1602415

成人血紅素血症檢測市場：按群體、類型和最終用戶分類 - 全球預測 2025-2030

Adult Hemoglobinopathy Testing Market by Group (Structural Hemoglobin Variants, Thalassemia Syndromes), Type (Hb Electrophoresis, HPLC Detection, Mass Spectrometry), End-Use - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年成人血紅素血症檢測市值為47.2億美元，預計2024年將達到51億美元，複合年成長率為6.17%，到2030年將達到71.8億美元。

成人血紅蛋白血症檢測與以成人血紅蛋白異常產生為特徵的遺傳性疾病（例如鐮狀細胞病和BETA地中海貧血）的診斷評估有關。此測試的範圍和定義包括基因篩檢、電泳和其他先進的診斷技術來識別血紅蛋白疾病。此測試對於促進早期診斷、評估嚴重程度和確定治療策略是必要的。應用範圍從產前篩檢到基於人群的研究，有助於最佳化個人化護理並改善公共衛生結果。最終用戶主要包括醫院、診斷實驗室和研究機構。由於意識的提高、基因檢測方法的技術進步以及新興市場的政府舉措，血紅蛋白病患病率上升對市場成長產生了重大影響。研究表明，將人工智慧和機器學習整合到診斷過程中可以透過提高準確性和降低成本提供重要的商機，而生物技術公司和研究機構之間的合作可以進一步推動創新。然而，市場面臨挑戰，包括檢測技術高成本、資源匱乏環境下的訪問受限以及對熟練醫療保健專業人員的需求。此外，設備和操作的高成本也是小型測試設施採用的障礙。有開發具有成本效益的高通量篩檢方法和攜帶式診斷的創新和研發機會。此外，CRISPR 和基因編輯技術的進步可能會提供治療解決方案，並代表另一種研究和開發途徑。市場的競爭性和協作性需要策略夥伴關係來進行業務擴展和研發投資。上市公司應專注於廣泛的可及性和可負擔性，同時與公共衛生機構合作克服監管障礙。成功的進入者和現有企業應致力於透過技術調整優先考慮差異化並解決農村和服務不足人口的未滿足需求，從而有效佔領市場。

主要市場統計
基準年[2023] 47.2億美元
預測年份 [2024] 51億美元
預測年份 [2030] 71.8億美元
複合年成長率（%） 6.17%

市場動態：快速發展的成人血紅蛋白血症檢測市場的關鍵市場洞察

成人血紅蛋白血症檢測市場正因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 地中海貧血和鐮狀細胞疾病 (SCD) 的全球盛行率
    • 疾病的早​​期診斷和治療趨勢
    • 需要持續的新生兒篩檢計劃和準確可靠的檢測方法
  • 市場限制因素
    • 成人血紅素血症檢測相關的高成本
  • 市場機會
    • 成人血紅素病檢測方法的技術進步
    • 成人血紅蛋白病的持續研究與開發
  • 市場挑戰
    • 成人血紅素血症檢測設備的技術限制

波特五力：駕馭成人血紅素血症檢測市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解外部對成人血紅素血症檢測市場的影響

外部宏觀環境因素在塑造成人血紅蛋白血症檢測市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解成人血紅素血症檢測市場的競爭狀況

成人血紅素血症測試市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣成人血紅素血症測試市場供應商的績效評估

FPNV 定位矩陣是評估成人血紅素血症測試市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，規劃成人血紅素血症檢測市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，成人血紅蛋白血症測試市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球地中海貧血和鐮狀細胞疾病 (SCD) 的盛行率
      • 疾病的早​​期診斷和治療趨勢
      • 新生兒篩檢計劃的繼續以及對準確可靠的檢測方法的需求
    • 抑制因素
      • 成人血紅素病檢測相關的高成本
    • 機會
      • 成人血紅素病檢測方法的技術進步
      • 成人血紅蛋白病的持續研究與開發
    • 任務
      • 成人血紅素病檢測設備的技術限制
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章成人血紅素血症檢測市場（依群體）

  • 結構性血紅素變異
  • 地中海貧血症候群

第7章成人血紅素血症檢測市場：依類型

  • 血紅素電泳
  • 高效液相層析檢測
  • 質譜分析

第8章成人血紅素血症檢測市場：依最終用途分類

  • 醫院
  • 研究所
  • 醫學研究機構

第9章 北美和南美成人血紅素血症檢測市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區成人血紅素血症檢測市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲成人血紅素血症檢測市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • ARKRAY, Inc.
  • Beckman Coulter, Inc. by Danaher Corporation
  • Bio-Rad Laboratories, Inc.
  • Bluebird Bio, Inc.
  • Creative Diagnostics
  • F. Hoffmann-La Roche Ltd.
  • HORIBA Group
  • Illumina, Inc.
  • Laboratory Corporation of America Holdings
  • Merck KGaA
  • PerkinElmer, Inc.
  • Quest Diagnostics Incorporated
  • Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • Shimadzu Corporation
  • Siemens Healthineers AG
  • Sysmex Europe SE
  • Thermo Fisher Scientific Inc.
  • Tosoh Corporation
  • Trinity Biotech PLC
Product Code: MRR-C002B1C99763

The Adult Hemoglobinopathy Testing Market was valued at USD 4.72 billion in 2023, expected to reach USD 5.10 billion in 2024, and is projected to grow at a CAGR of 6.17%, to USD 7.18 billion by 2030.

Adult hemoglobinopathy testing pertains to the diagnostic evaluation of inherited disorders characterized by abnormal hemoglobin production, such as sickle cell disease and beta-thalassemia, in adults. The scope and definition of this testing encompass genetic screenings, electrophoresis, and other advanced diagnostic techniques to identify hemoglobinopathies. This testing is necessary for promoting early diagnosis, assessing severity, and guiding treatment decisions. Its applications range from prenatal screenings to population-based studies, serving in optimizing individualized care and improving public health outcomes. End-users primarily include hospitals, diagnostic laboratories, and research institutions. The market's growth is significantly influenced by a rising prevalence of hemoglobinopathies due to increased awareness, technological advancements in genetic testing methods, and government initiatives in emerging markets. Insights reveal that integrating AI and machine learning in diagnostic processes presents substantial opportunities by enhancing accuracy and reducing costs, while collaborations between biotech firms and research organizations can further spur innovation. However, the market faces challenges like high costs of testing technologies, limited access in low-resource settings, and a need for skilled healthcare professionals. High equipment and operational costs can also deter smaller laboratories from adoption. Innovation and research opportunities lie in developing cost-effective, high-throughput screening methods and portable diagnostics that could democratize accessibility. Furthermore, advancements in CRISPR and gene-editing technologies could potentially offer therapeutic solutions, highlighting another avenue for research and development. The market's nature is competitive yet collaborative, necessitating strategic partnerships for expansion and R&D investment. Companies should focus on broad accessibility and affordability, collaborating with public health entities to navigate regulatory hurdles. Successful entrants and established firms should prioritize differentiation through technological adaptation, addressing the unmet needs in rural and underserved populations for effective market capture.

KEY MARKET STATISTICS
Base Year [2023] USD 4.72 billion
Estimated Year [2024] USD 5.10 billion
Forecast Year [2030] USD 7.18 billion
CAGR (%) 6.17%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Adult Hemoglobinopathy Testing Market

The Adult Hemoglobinopathy Testing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Prevalence of thalassemia and sickle cell disease (SCD) worldwide
    • Inclination toward early diagnosis and treatment of diseases
    • Ongoing newborn screening programs and need for accurate and reliable testing methodologies
  • Market Restraints
    • High cost associated with adult-hemoglobinopathy-testing
  • Market Opportunities
    • Technological advancements in adult-hemoglobinopathy-testing methods
    • Ongoing research and development on adult-hemoglobinopathy
  • Market Challenges
    • Technical limitations in devices used for adult-hemoglobinopathy-testing

Porter's Five Forces: A Strategic Tool for Navigating the Adult Hemoglobinopathy Testing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Adult Hemoglobinopathy Testing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Adult Hemoglobinopathy Testing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Adult Hemoglobinopathy Testing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Adult Hemoglobinopathy Testing Market

A detailed market share analysis in the Adult Hemoglobinopathy Testing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Adult Hemoglobinopathy Testing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Adult Hemoglobinopathy Testing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Adult Hemoglobinopathy Testing Market

A strategic analysis of the Adult Hemoglobinopathy Testing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Adult Hemoglobinopathy Testing Market, highlighting leading vendors and their innovative profiles. These include ARKRAY, Inc., Beckman Coulter, Inc. by Danaher Corporation, Bio-Rad Laboratories, Inc., Bluebird Bio, Inc., Creative Diagnostics, F. Hoffmann-La Roche Ltd., HORIBA Group, Illumina, Inc., Laboratory Corporation of America Holdings, Merck KGaA, PerkinElmer, Inc., Quest Diagnostics Incorporated, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Shimadzu Corporation, Siemens Healthineers AG, Sysmex Europe SE, Thermo Fisher Scientific Inc., Tosoh Corporation, and Trinity Biotech PLC.

Market Segmentation & Coverage

This research report categorizes the Adult Hemoglobinopathy Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Group, market is studied across Structural Hemoglobin Variants and Thalassemia Syndromes.
  • Based on Type, market is studied across Hb Electrophoresis, HPLC Detection, and Mass Spectrometry.
  • Based on End-Use, market is studied across Hospital, Laboratories, and Medical & Research Institute.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of thalassemia and sickle cell disease (SCD) worldwide
      • 5.1.1.2. Inclination toward early diagnosis and treatment of diseases
      • 5.1.1.3. Ongoing newborn screening programs and need for accurate and reliable testing methodologies
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with adult-hemoglobinopathy-testing
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements in adult-hemoglobinopathy-testing methods
      • 5.1.3.2. Ongoing research and development on adult-hemoglobinopathy
    • 5.1.4. Challenges
      • 5.1.4.1. Technical limitations in devices used for adult-hemoglobinopathy-testing
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Adult Hemoglobinopathy Testing Market, by Group

  • 6.1. Introduction
  • 6.2. Structural Hemoglobin Variants
  • 6.3. Thalassemia Syndromes

7. Adult Hemoglobinopathy Testing Market, by Type

  • 7.1. Introduction
  • 7.2. Hb Electrophoresis
  • 7.3. HPLC Detection
  • 7.4. Mass Spectrometry

8. Adult Hemoglobinopathy Testing Market, by End-Use

  • 8.1. Introduction
  • 8.2. Hospital
  • 8.3. Laboratories
  • 8.4. Medical & Research Institute

9. Americas Adult Hemoglobinopathy Testing Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Adult Hemoglobinopathy Testing Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Adult Hemoglobinopathy Testing Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. ARKRAY, Inc.
  • 2. Beckman Coulter, Inc. by Danaher Corporation
  • 3. Bio-Rad Laboratories, Inc.
  • 4. Bluebird Bio, Inc.
  • 5. Creative Diagnostics
  • 6. F. Hoffmann-La Roche Ltd.
  • 7. HORIBA Group
  • 8. Illumina, Inc.
  • 9. Laboratory Corporation of America Holdings
  • 10. Merck KGaA
  • 11. PerkinElmer, Inc.
  • 12. Quest Diagnostics Incorporated
  • 13. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • 14. Shimadzu Corporation
  • 15. Siemens Healthineers AG
  • 16. Sysmex Europe SE
  • 17. Thermo Fisher Scientific Inc.
  • 18. Tosoh Corporation
  • 19. Trinity Biotech PLC

LIST OF FIGURES

  • FIGURE 1. ADULT HEMOGLOBINOPATHY TESTING MARKET RESEARCH PROCESS
  • FIGURE 2. ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ADULT HEMOGLOBINOPATHY TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. ADULT HEMOGLOBINOPATHY TESTING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ADULT HEMOGLOBINOPATHY TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ADULT HEMOGLOBINOPATHY TESTING MARKET DYNAMICS
  • TABLE 7. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY STRUCTURAL HEMOGLOBIN VARIANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY THALASSEMIA SYNDROMES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HB ELECTROPHORESIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HPLC DETECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY MEDICAL & RESEARCH INSTITUTE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 145. ADULT HEMOGLOBINOPATHY TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 146. ADULT HEMOGLOBINOPATHY TESTING MARKET, FPNV POSITIONING MATRIX, 2023